Positive data for Takeda insomnia treatment
In this placebo-controlled analysis, approximately two-thirds of patients who received 8mg of Rozerem experienced at least a 50% reduction in the time it took them to fall asleep.
The US Food and Drug Administration (FDA) is set to review Kowa Pharmaceuticals America’s new drug application (NDA) for K-911, an investigational once-daily eye drop aimed at reducing intraocular pressure (IOP) in open-angle glaucoma (OAG) or ocular hypertension (OHT) patients.